Lineage Cell Therapeutics - 29 Year Stock Price History | LCTX

Historical daily share price chart and data for Lineage Cell Therapeutics since 1992 adjusted for splits. The latest closing stock price for Lineage Cell Therapeutics as of September 27, 2021 is 2.67.
  • The all-time high Lineage Cell Therapeutics stock closing price was 26.19 on November 03, 1997.
  • The Lineage Cell Therapeutics 52-week high stock price is 3.13, which is 17.2% above the current share price.
  • The Lineage Cell Therapeutics 52-week low stock price is 0.92, which is 65.5% below the current share price.
  • The average Lineage Cell Therapeutics stock price for the last 52 weeks is 2.23.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Lineage Cell Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 2.5198 1.9300 3.1000 1.7700 2.6700 51.70%
2020 1.0404 0.8740 1.8300 0.6001 1.7600 97.75%
2019 1.0638 1.0400 1.7300 0.5400 0.8900 -2.52%
2018 2.2671 2.2900 3.1000 0.8600 0.9130 -57.53%
2017 2.9412 3.6400 3.7300 2.1500 2.1500 -40.44%
2016 3.0092 3.6800 3.9700 2.0800 3.6100 -11.95%
2015 3.9938 3.9400 5.8800 2.5300 4.1000 9.92%
2014 3.1909 3.6400 4.1300 2.2900 3.7300 3.61%
2013 3.9711 3.3100 4.9900 3.2000 3.6000 14.65%
2012 4.3414 6.1200 6.1200 2.9100 3.1400 -45.96%
2011 5.7384 8.9200 9.5000 3.7400 5.8100 -30.25%
2010 6.1336 4.7300 9.6900 4.1900 8.3300 96.93%
2009 3.1821 1.7500 6.4000 1.2500 4.2300 138.98%
2008 0.8647 0.3800 2.3000 0.2700 1.7700 331.71%
2007 0.4906 0.2600 0.7500 0.2600 0.4100 54.72%
2006 0.2891 0.3200 0.4900 0.1810 0.2650 -14.52%
2005 0.7226 1.5100 1.6700 0.2000 0.3100 -79.47%
2004 1.4994 1.4400 2.3600 0.8700 1.5100 9.42%
2003 1.7194 1.6300 2.7900 1.3000 1.3800 -10.97%
2002 2.3825 4.6300 4.7000 0.8500 1.5500 -66.30%
2001 6.8010 8.0000 11.1000 4.2200 4.6000 -38.67%
2000 8.6239 9.0000 18.0000 3.8130 7.5000 -15.49%
1999 12.5861 16.1200 18.8800 8.2500 8.8750 -48.94%
1998 10.7916 17.9400 17.9400 5.8800 17.3800 -8.53%
1997 13.1232 8.4167 26.1900 7.8333 19.0000 103.57%
1996 5.2654 1.2500 9.3333 0.8733 9.3333 794.59%
1995 0.7705 0.5833 1.7933 0.4567 1.0433 56.49%
1994 1.1901 2.6267 2.6267 0.5833 0.6667 -74.62%
1993 3.1186 3.2500 3.5000 2.5433 2.6267 -19.18%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.447B $0.002B
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29